ARV access in resource-poor countriesHighly anticipated special issue with UNAIDS now available
2015 Subscriptions availableOrder the next volume of Antiviral Therapy today.
Follow us on TwitterInternational Medical Press is now on Twitter. Join our conversation today.
International Medical Press publishes Antiviral Therapy.
Antiviral Therapy is one of the leading journals in virology (2013 ISI impact factor: 3.14). The journal is devoted to publishing high quality articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases.
♦ Online submission and manuscript tracking via ScholarOne Manuscripts™
♦ Leading Editorial Boards ensuring high-quality standards
♦ Immediate online publication of all non-commissioned articles
♦ Inclusion in major indexing and abstracting services
♦ Worldwide readership
Recently published in Antiviral Therapy
Rimsky et al. report long-term resistance to rilpivirine in the ECHO/THRIVE Phase III trials. At 96 weeks, resistance patterns were consistent with 48-week data, and suggest most virological failures and resistance-associated mutations occur during the first year of treatment. Overall, the evidence demonstrates rilpivirine is non-inferior to existing therapies for HIV-infected, treatment-naive patients. Read more here.
The Editorial Office welcomes queries about publishing supplements within the journal. Please visit the Supplements page for more information.